PT-141
Research use only.
High-purity research peptide for laboratory use
PT-141 (Bremelanotide) is a synthetic melanocortin peptide analog derived from α-MSH and is widely studied for its effects on central nervous system pathways related to arousal, motivation, and behavioral response. Unlike peptides that act peripherally, PT-141 is primarily investigated for its central mechanism of action involving melanocortin receptors in the brain.
Product overview
PT-141 is a research peptide engineered to selectively activate melanocortin receptors, particularly MC3R and MC4R, which play key roles in neuroendocrine signaling and behavioral regulation. Preclinical and clinical research associate PT-141 with modulation of desire, motivation, and autonomic nervous system activity, making it a valuable tool for studies involving central arousal pathways and psychoneuroendocrinology.
Key research features
Central arousal and motivation pathways:
PT-141 is widely studied for its ability to influence brain-based arousal signaling independent of vascular mechanisms. Research models explore its role in motivation, reward circuitry, and behavioral responsiveness.
Neuroendocrine signaling research:
Studies suggest PT-141 may modulate hypothalamic and autonomic pathways involved in hormonal and behavioral regulation, supporting its use in experimental models of sexual function and CNS-driven response mechanisms.
Stress and autonomic response modulation:
Research indicates PT-141 may influence sympathetic and parasympathetic balance through central receptor activation, making it relevant for studies examining stress response, mood, and neurobehavioral interactions.
PT-141 Suggested Use:
Typical Dose: 1–2 mg per injection
Route: Subcutaneous
Frequency: As needed, up to once daily
Duration: Short-term use, or as recommended by a healthcare professional